\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Security Digital, Industry & Space Cybersecurity Defence NATO-EDAApplications are open until 15 November 2024
About the Programme
The NATO Chief Scientist Grants Programme is dedicated to fostering excellence in science and technology research. It is committed to supporting groundbreaking projects that contribute to global security and scientific advancement. The programme particularly encourages applications from qualified women in STEM fields, recognizing the vital importance of diverse perspectives in addressing complex security challenges.
In 2025, the programme will award 500,000 Euros in total to fund the following types of activities:
*Please note that grants may vary in size, but typically they will range between 25,000 and 100,000 Euros.
More information on the website of NATO Chief Scientist Grants
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
